Hecht Jonathan L, Ince Tan A, Baak Jan P A, Baker Heather E, Ogden Maryann W, Mutter George L
Department of Pathology, Beth Israel Hospital, Boston, MA 02115, USA.
Mod Pathol. 2005 Mar;18(3):324-30. doi: 10.1038/modpathol.3800328.
Endometrial intraepithelial neoplasia (also known as 'EIN') is a precursor to endometrioid endometrial adenocarcinoma characterized by monoclonal growth of mutated cells, a distinctive histopathologic appearance, and 45-fold elevated cancer risk. We have applied diagnostic criteria for EIN to 97 successive endometrial biopsies classified as hyperplastic according to World Health Organization criteria and correlated results with computer-assisted morphometry (D-score) and clinical cancer outcomes. Three pathologists separately reviewed all cases for presence or absence of EIN using published criteria (gland area>stromal area, cytologic change in focus of altered architecture, lesion size>1 mm, and exclusion of cancer and mimics). Discordant cases were resolved by a consensus review at a multiheaded scope. Clinical outcomes were obtained in 84 patients from patient visit and pathology records. Diagnoses of presence or absence of EIN were unanimous among all three pathologists in 75% of cases, and intraobserver-reproducibility was very good (kappa 0.73-0.90). Cases rediagnosed as EIN encompassed hyperplasias previously diagnosed as atypical (n=18) or nonatypical (eight complex, two simple). Eight follow-up cancers were scattered between hyperplasia types (5/21 atypical, 3/63 nonatypical), but all classified as EIN (8/25) and D-score <or=1 (8/38). Subjective application of criteria for diagnosis of EIN correlates well with objective morphometry and successfully segregates patients into high and low cancer risk subgroups with better reproducibility than atypical hyperplasia diagnosis.
子宫内膜上皮内瘤变(也称为“EIN”)是子宫内膜样腺癌的前驱病变,其特征为突变细胞的单克隆生长、独特的组织病理学表现以及癌症风险升高45倍。我们已将EIN的诊断标准应用于97例连续的子宫内膜活检,这些活检根据世界卫生组织标准被分类为增生性病变,并将结果与计算机辅助形态计量学(D评分)及临床癌症结局相关联。三位病理学家分别使用已发表的标准(腺体面积>间质面积、结构改变部位的细胞学变化、病变大小>1mm,以及排除癌症和类似病变)对所有病例进行EIN的有无评估。不一致的病例通过多头显微镜下的共识审查来解决。通过患者就诊和病理记录获得了84例患者的临床结局。在75%的病例中,三位病理学家对EIN有无的诊断一致,观察者内再现性非常好(kappa值为0.73 - 0.90)。重新诊断为EIN的病例包括先前诊断为非典型增生(n = 18)或非非典型增生(8例复杂性增生、2例单纯性增生)的增生性病变。8例随访期发生的癌症分散在不同增生类型之间(非典型增生21例中的5例,非非典型增生63例中的3例),但均被分类为EIN(25例中的8例)且D评分≤1(38例中的8例)。EIN诊断标准的主观应用与客观形态计量学相关性良好,并成功地将患者分为癌症高风险和低风险亚组,其再现性优于非典型增生诊断。